I'm LongbridgeAI, I can summarize articles.InnoCare Pharma (9969.HK) climbed nearly 6% in Hong Kong trading to HK$11.77.
The stock is down 6.36% over the past ten sessions and sits 21.97% above its 52-week low of HK$9.650.
The Hang Seng Index is up 2.72% over the past five sessions and down 7.44% year to date.
The biotechnology industry index rose 6.0% over the same period.
The company reported first-three-quarter revenue of 2.099 billion yuan, up 88.21% from a year earlier, and net income of 648 million yuan, swinging to a profit.
Separately, ICP-B161, a novel bispecific antibody targeting TL1A and IL-23p19 developed for inflammatory bowel disease and other autoimmune conditions, has completed first-patient dosing in a Phase I trial. InnoCare also presented clinical data at the ESMO Congress showing an 89.5% response rate for orelabrutinib-based combination therapy in treatment-naive marginal zone lymphoma patients.
Based on public media reports. AI-generated; not investment advice.
